Clinical study of ziprasidone injection in the treatment of agitation in acute schizophrenia

Objective To investigate the clinical effect of ziprasidone injection in the treatment of schizophrenic agitation patients. Methods A total of 118 schizophrenic agitation patients who were treated in Mental Health Center, School of Medicine, Shanghai Jiaotong University from January 2017 to January 2019 were enrolled. They were randomly divided into two groups (n=59): an observation group and a control group. The observation group was treated with ziprasidone, while the control group was treated with haloperidol for three days. Both groups were compared for PANSS score, PANSS-EC score and BARS score. Their incidences of adverse reactions were observed. Results The total effective rate of the observation group (89.83%) was significantly higher than that of the control group (74.58%) (χ²=4.692, P=0.030). After 30 min and 2 h of treatment, the PANSS-EC and BARS scores of the two groups significantly decreased, and the PANSS-EC (t=3.401, 9.812, P<0.05) and BAR scores (t=2.120, 2.519, P<0.05) of the observation group were significantly lower than those of the control group. There was no significant difference between the two groups in sedentary disability (χ²=0.165, P=0.684), weight gain (χ²=0.521, P=0.470), dry mouth constipation (χ²=0.179, P=0.672) and tachycardia (χ²=0.202, P=0.657). Conclusions Ziprasidone injection can effectively treat schizophrenic agitation patients, with decreased PANSS score, PANSS-EC and BARS scores.